A complex system of endocrine and paracrine signals exists to control phosphate balance. Dysregulation of these systems in patients with chronic kidney disease has serious clinical consequences. Whilst observational studies have shown associations between higher serum phosphate levels and poor clinical outcomes, the direction of causality has not been demonstrated. Whether there is a target level of serum phosphate remains controversial and no randomized trials to date have proved that strategies to lower extracellular phosphate actually improve clinical outcomes. Serum phosphate provides only a partial measure of overall phosphate balance and, importantly, calcification risk. Changes in dietary phosphate may be a modifiable source of phosphate in humans, although better methods for assessment of dietary phosphate intake are required. Individuals consume large amounts of phosphate in processed foods, rich in phosphate additives, and there is interest in restricting dietary phosphate as a matter of public health, although the association between dietary phosphate and serum phosphate is modest at best. Interventional studies are needed to provide supportive evidence of any potential advantages of dietary phosphate restriction before such measures can be recommended.
ABSTRACT:
A complex system of endocrine and paracrine signals exists to control phosphate balance. Dysregulation of these systems in patients with chronic kidney disease has serious clinical consequences. Whilst observational studies have shown associations between higher serum phosphate levels and poor clinical outcomes, the direction of causality has not been demonstrated. Whether there is a target level of serum phosphate remains controversial and no randomized trials to date have proved that strategies to lower extracellular phosphate actually improve clinical outcomes. Serum phosphate provides only a partial measure of overall phosphate balance and, importantly, calcification risk. Changes in dietary phosphate may be a modifiable source of phosphate in humans, although better methods for assessment of dietary phosphate intake are required. Individuals consume large amounts of phosphate in processed foods, rich in phosphate additives, and there is interest in restricting dietary phosphate as a matter of public health, although the association between dietary phosphate and serum phosphate is modest at best. Interventional studies are needed to provide supportive evidence of any potential advantages of dietary phosphate restriction before such measures can be recommended.
SERUM PHOSPHATE AND ADVERSE OUTCOMES
Phosphate is essential for life, serving as a structural component of nucleic acids, adenosine triphosphate and phospholipids in membranes, as well as playing a critical role in cellular signalling through phosphorylation reactions. 'Normal' serum phosphate levels are dependent upon the absorption of dietary phosphate in the gut, the reabsorption and excretion of phosphate in the kidney, and the flux of phosphate between the extracellular and skeletal pools. Therefore, phosphate homeostasis is coordinated by complex interactions between the intestine, parathyroid glands, kidneys and bone. Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) both play an important role in regulating serum phosphate by stimulating urinary phosphate excretion. Phosphate is freely filtered through the glomerulus and reabsorbed via the renal sodium/phosphate type 2 cotransporters NaPi-2a and NaPi-2c, which are expressed on the luminal side of the proximal tubular epithelial cells. How, or even if, humans 'sense' and control extracellular phosphate remains unclear, and no extracellular phosphate sensor has been described to date. Phosphate elimination is dependent upon renal function, such that positive phosphate balance occurs relatively early in renal dysfunction but serum phosphate levels rise only late in chronic kidney disease (CKD) and remain elevated in patients on dialysis without treatment. Hyperphosphataemia is recognized as an independent risk factor for accelerated vascular disease in CKD. 1 19 The guidelines also stated that it is 'biologically plausible' that elevated serum phosphate levels contribute to the causation of complications of CKD-MBD and therefore there is a rationale for suggesting lowering phosphate levels in patients with CKD stages 3-5D. Nevertheless, KDIGO had weak clinical evidence for the statement that 'phosphate reduction directly improves outcomes' because these statements are based purely upon associative data. The guidelines also suggested that calcitriol, phosphate binders and dialysis can be used to manipulate serum phosphate levels, but admit there is a lack of randomized controlled trials to demonstrate that lowering phosphate affects outcomes. Furthermore, the guidelines described that in some patients with CKD, treatment may not be possible and targets unachievable, supporting the need for therapy to be individualized. The current draft, soon to be published KDIGO guidelines (http://www.kdigo.org/clinical_practice_guidelines/CKDMBD%20Update/KDIGO%20CKD-MBD%20Update_Public %20Review_Final.pdf: last accessed 22 January 2017), highlighted that trial data demonstrating treatments to lower serum phosphate and improve patient-centred outcomes are still lacking, and the rationale for any phosphate-lowering interventions is still only based on epidemiological evidence and biological plausibility. Although several recent historical cohort analyses (DOPPS, ArMORR and COSMOS) suggested that dialysis patients who had been prescribed phosphate binders showed improved survival, 20-22 they were not included as part of the evidence-based review for the revision of the KDIGO guidelines. However, a recent randomized controlled trial, which was included in the guideline update review comparing phosphate binders with placebo in patients with CKD stages 3-4, reported minimal declines within the active treatment groups in serum phosphate, no overall effect on FGF23, and increases in coronary calcification for the combined phosphate binder groups. 23 These results question the efficacy and safety of phosphate binders in this population with normal serum phosphate levels. Revision of the KDIGO guidelines has therefore abandoned the previous suggestion to maintain serum phosphate in the normal range for patients with CKD stages 3-5, and instead were updated to suggest that treatment should focus on patients with overt hyperphosphataemia, although still based on weak clinical evidence.
IS TARGETING SERUM PHOSPHATE APPROPRIATE IN PATIENTS WITH CHRONIC KIDNEY DISEASE?
One of the central tenets of the very 'phospho-centric' hypothesis of CKD-MBD, is that phosphate alone is a cellular toxin, but there are problems with this hypothesis. Human neonates and many animal species have much higher levels of serum phosphate than many dialysis patients; for example, phosphate levels in human neonates range between 1.4-2.6 mmol/L and in rats range between approximately 2-3 mmol/L, suggesting that the body has evolved other strategies to cope with higher extracellular levels. Furthermore, phosphate levels vary with age, throughout the day, and are affected by food intake. Whilst there is little doubt that for growing cells in a culture medium, very high phosphate levels induce cellular dysfunction and apoptosis, it should be noted that many of these experiments have been conducted with supra-physiological calcium and/or inorganic phosphate concentrations. Additionally, phosphate toxicity is almost completely abrogated by pyrophosphate, a compound that inhibits calcium apatite crystal (Ca 10 (PO 4 ) 6 (OH) 2 ) formation and nanocrystalisation. 24 Phosphonoformic acid at low concentrations also reduces phosphate toxicity and has often been cited as a specific cellular phosphate uptake inhibitor, but it also inhibits apatite crystal formation. 25 Finally, if calcium is removed from the milieu, phosphate-induced cellular dysfunction is completely prevented. 26 These and other evidence suggest phosphate is at best only indirectly toxic and that cellular toxicity may instead be mediated by calcium and phosphate nanocrystals, with or without protein inhibitors, that form in culture media. 16 Controlled studies of phosphate binders compared with placebo generally show only moderate or no effects in reducing Phosphate in CKD cardiovascular complications or mortality in dialysis patients. Moreover, the data fail to support phosphate reduction as the mechanism for these effects. [20] [21] [22] 27, 28 For example, Winkelmayer et al. studied mortality in incident patients starting dialysis with either calcium-based phosphate binders or no binder. 28 The calcium-based binder group had a lower overall mortality but higher phosphate; however, when propensity score matched, there was no difference between groups. In a prospective study of incident haemodialysis patients, Isakova et al. examined a cohort treated with or without phosphate binders for the first 90 days of dialysis. 21 After adjusting for known co-variates, survival favoured those on binder therapy, but survival was independent of the serum phosphate result. Cannata-Andia et al. published a placebocontrolled study suggesting that phosphate binder use was associated with better survival on haemodialysis, but here patients in the phosphate binder group had higher serum phosphate levels than controls and the advantage was seen across all levels of serum phosphate, even low levels. 20 Finally, bone buffering and turnover is likely to contribute significantly to changes in serum phosphate levels, suggesting that any studies of therapies targeting phosphate uptake alone, whilst ignoring what is happening at bone surfaces, are likely to be imperfect. Thus, it is entirely unclear that measuring serum phosphate alone as a key target in patients with CKD is helpful. However, phosphate levels may act as a prognostic indicator and as a guide to management with dialysis dosing, medication prescription and dietary adherence. Serum phosphate is only one factor in a complex disease process which we do not yet fully comprehend. Whilst extracellular phosphate levels may be of some importance to a pathway that leads to cellular dysfunction, the inference that a measurement of phosphate alone is of major importance is probably somewhat facile. Furthermore, what useful or achievable phosphate targets should be in pre-dialysis and dialysis patients remains unclear. Several animal and human studies have suggested that a low phosphate diet may slow the progression of CKD. [40] [41] [42] However, phosphate restriction is not always practical and may be associated with reduced protein intake. Low phosphate diets may also upregulate gastrointestinal NaPi-2b expression independent of calcitriol, although the mechanism of this regulation remains unclear.
DIETARY PHOSPHATE AND SERUM PHOSPHATE

Effects on fibroblast growth factor 23
Disordered regulation of FGF23 by high dietary phosphate may possibly be a key factor contributing to atherosclerosis and increased cardiovascular burden in patients with CKD. Studies have reported that FGF23 levels appear to be responsive to changes in diet in both CKD patients and controls. 43 In a 3 month cross-over study of 39 patients with CKD stages 3 and 4 and normal serum phosphate levels, reducing dietary phosphate intake or absorption was reported to decrease FGF23 levels, most effectively with a combination of phosphate-restricted diet and binders. 30 Toussaint ND and Holt SG
Effects on vascular calcification and bone
In one randomized controlled trial of 90 phosphate-binder-naive patients with CKD stages 3-5 not on dialysis, Russo et al. assessed the effect of dietary phosphate restriction on vascular calcification. 44 Although this study was not designed to show superiority or an equivalence of dietary phosphate modification compared with phosphate binders, coronary artery calcification scores were increased in the group receiving phosphaterestricted diet alone and in the group receiving diet in combination with calcium carbonate as a phosphate binder whereas there was no progression of calcification in the diet-plussevelamer-treated group. In another study, using bone biopsy in 16 patients with CKD stages 4-5, Lafage-Proust et al. reported that after 5 years of very-low-protein, low-phosphate diets supplemented with essential amino acids and their ketoanalogs, the bone-formation rate was normal or high in 10 patients, and low in the remaining six. 45 They did not observe any low-protein-associated malnutrition in these patients.
Dietary phosphate bioavailability and additives
The type of the diet also has considerable impact on intestinal phosphate absorption. The modern diet often contains high levels of phosphate in the form of preservatives and additive salts that are readily absorbed by the intestine, whereas phosphates in plants are often complexed in the form of phytates and have lower bioavailability. A recent study by Moe et al. evaluated differences between meat-based and vegetarianbased diets suggesting that vegetarian diets were associated with lower serum phosphate and FGF23 levels despite both diets providing similar overall phosphate content. 29 Targeting a lower dietary phosphate content or reduced food additives has been reported to be effective in haemodialysis patients leading to a reduction in serum phosphate over a 6-month period. 46, 47 A newer approach to reducing phosphate absorption is by targeting the electroneutral sodium/hydrogen exchangers (NHE), in particular NHE3. The NHE3 inhibitor tenapanor has been shown to reduce enteric phosphate absorption in rats and prevents vascular calcification although clinical studies evaluating benefits on outcomes in humans are pending. 48 
WHAT IS THE ROLE OF DIETARY PHOSPHATE RESTRICTION IN CHRONIC KIDNEY DISEASE PATIENTS?
The KDIGO CKD-MBD guidelines state there are insufficient data at present to strongly endorse dietary phosphate restriction as the primary intervention for the management of CKD-MBD, especially for dialysis patients. 19 It is biologically plausible that such diets are helpful in early CKD and as an adjunct to phosphate binders and dialytic removal in dialysis patients. The limited safety data suggest that dietary phosphate restriction does not necessarily compromise nutrition. There is a lack of evidence evaluating the potential benefits of modification of dietary phosphate, either through reduced intake with dietary restriction or with reduced absorption using phosphate binders. Indeed, an extremely low phosphate intake in conjunction with low protein intake may be associated with worse outcome. Large randomized controlled trials may be needed to prove or disprove any benefits, risks or potential economic impact of dietary phosphate lowering in CKD, though the feasibility of such studies suggests they are unlikely to be performed.
